Stockscreener 앱 받기
2.885
4.65%
-0.125
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine Inc (PRME) Cash Flow - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Market Sentiment - Benzinga España
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PRME|Prime Medicine Inc|Price:3.015|Chg%:+0.065 - TradingKey
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Prime Medicine, Inc. (PRME) and Community Health (CYH) - The Globe and Mail
Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Price to earnings forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
First Trust Heitman Glbl Prm Rl Estt ETF (PRME) stock price, news, quote and history - Yahoo Finance UK
Prime Medicine Buy Rating Reiterated as Pipeline Advances; $6 Price Target Maintained - TipRanks
PRME|Prime Medicine Inc|Price:2.950|Chg%:-0.020 - TradingKey
Prime Medicine receives FDA clearance for Wilson disease therapy - Investing.com
Prime Medicine Announces U.S. FDA Clearance Of Investigational New Drug Application For Pm577a In H1069q-Mutated Wilson Disease - TradingView
Prime Medicine, Inc. (PRME) stock price, news, quote and history - Yahoo Finance Singapore
Prime Medicine receives FDA clearance for Wilson disease therapy By Investing.com - Investing.com Canada
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease - The Manila Times
Prime Medicine expects first-in-human Wilson trial in second half of 2026 - Stock Titan
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug - Stocktwits
Svetlana Ni Makhni Net Worth (2026) - GuruFocus
Prime Medicine secures favorable arbitration ruling in Beam Therapeutics case - MSN
Tracking Cathie Wood: Loading Up on X-Energy and Prime Medicine, Slashing AtaiBeckley - Moomoo
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Has $10.23 Million Stock Position in Prime Medicine, Inc. $PRME - MarketBeat
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Prime Medicine (NASDAQ:PRME) Shares Down 6.5%Should You Sell? - MarketBeat
Prime Medicine Stock Dips As Traders Weigh Heavy Losses - timothysykes.com
Enterprise value to EBITDA forward of Prime Medicine, Inc. – NASDAQ:PRME - TradingView
Prime Medicine gains after winning arbitration with Beam Therapeutics - MSN
PRME Stock Slides As Traders Weigh Heavy Losses And Cash Runway - StocksToTrade
Prime Medicine Down Nearly 14%, on Pace for Largest Percent Decrease Since May 2025 -- Data Talk - Moomoo
H.C. Wainwright reiterates Prime Medicine stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Prime Editing Clears IP Fight, Sets Q3 Filing for First Liver-Targeted AATD Drug - Tech Times
Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME) - The Globe and Mail
Prime Medicine wins arbitration to advance gene editing program, shares jump over 15%. - Pluang
Prime Medicine Beats Beam Therapeutics In Patent DisputeBut Both Are Investable (PRME) - Seeking Alpha
Morgan Stanley Maintains Prime Medicine(PRME.US) With Hold Rating - Moomoo
Prime Medicine stock surges after winning arbitration with Beam - Investing.com
Prime Medicine, Inc. (NASDAQ:PRME) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Prime Medicine Jumps 15% as Arbitration Win Clears Path for AATD Gene-Editing Human Trials - finance.biggo.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win By Investing.com - Investing.com South Africa
Prime Medicine Receives Favorable Ruling in Beam Therapeutics License Arbitration; Shares Rise - marketscreener.com
TD Cowen reiterates Buy on Prime Medicine stock after arbitration win - Investing.com Nigeria
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case - Benzinga
Prime Medicine wins binding arbitration against Beam Therapeutics - grafa.com
Prime Medicine Shares Rise on Positive Arbitration Ruling in Beam Dispute - Moomoo
LifeSci Capital Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Prime Medicine stock surges after winning arbitration with Beam By Investing.com - Investing.com Canada
Why is Prime Medicine stock surging today? By Investing.com - Investing.com Canada
0.96%
0.92%
자본화:
|
볼륨(24시간):